AR004158A1 - Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto. - Google Patents

Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto.

Info

Publication number
AR004158A1
AR004158A1 ARP970103380A ARP970103380A AR004158A1 AR 004158 A1 AR004158 A1 AR 004158A1 AR P970103380 A ARP970103380 A AR P970103380A AR P970103380 A ARP970103380 A AR P970103380A AR 004158 A1 AR004158 A1 AR 004158A1
Authority
AR
Argentina
Prior art keywords
compound
ftalizin
dionas
pirido
preparation
Prior art date
Application number
ARP970103380A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR004158A1 publication Critical patent/AR004158A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ftalazin-pirido-dionas que tienen la fórmula (I), donde R1 y R2 se seleccionan entre el grupo integrado por hidrógeno, halógeno, y metoxi ó dondeR1 y R2 juntos forman metilendioxi y sales farmacéuticamente aceptables de las mismas, y compos icionesfarmacéuticas que contienen una cantidad del mismosefectiva como antagonista de glicinaB, son útiles para combatir los trastornos neurológicos asociados con la excitotoxicidad y el mal funcionamiento de laneurotransmisión glutamatérgica en u nanimal vivo, incluido el ser humano, que tenga necesidad de ello. La invención también se refiee a un proceso parapreparar dichos compuestos que comprende convertir el derivado de quinolina correspondiente en la sal de hidrazina e hidrolizar l asal resultante paraproducir el compuesto deseado.
ARP970103380A 1996-07-25 1997-07-25 Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto. AR004158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission

Publications (1)

Publication Number Publication Date
AR004158A1 true AR004158A1 (es) 1998-11-04

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970103380A AR004158A1 (es) 1996-07-25 1997-07-25 Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto.

Country Status (31)

Country Link
US (1) US5776935A (es)
EP (1) EP0931081B1 (es)
JP (1) JP3595342B2 (es)
KR (1) KR100598206B1 (es)
CN (1) CN1093860C (es)
AR (1) AR004158A1 (es)
AT (1) ATE224894T1 (es)
AU (1) AU719993B2 (es)
BR (1) BR9710569A (es)
CA (1) CA2261923C (es)
CZ (1) CZ289293B6 (es)
DE (1) DE69715893T2 (es)
DK (1) DK0931081T3 (es)
EA (1) EA001711B1 (es)
ES (1) ES2180041T3 (es)
FI (1) FI112946B (es)
GE (1) GEP20022801B (es)
HK (1) HK1020193A1 (es)
HU (1) HU223780B1 (es)
IL (1) IL128225A (es)
LT (1) LT4591B (es)
LV (1) LV12260B (es)
NO (1) NO310820B1 (es)
PL (1) PL189572B1 (es)
PT (1) PT931081E (es)
SI (1) SI9720048B (es)
SK (1) SK283536B6 (es)
TW (1) TW402605B (es)
UA (1) UA63911C2 (es)
WO (1) WO1998004556A1 (es)
ZA (1) ZA976612B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
WO2003015713A2 (en) * 2001-08-20 2003-02-27 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR102609676B1 (ko) 2017-06-12 2023-12-05 글리테크 엘엘씨. Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
LT4591B (lt) 1999-12-27
PL189572B1 (pl) 2005-08-31
PL331323A1 (en) 1999-07-05
SI9720048B (sl) 2002-02-28
DE69715893D1 (de) 2002-10-31
EA001711B1 (ru) 2001-06-25
AU4296997A (en) 1998-02-20
HU223780B1 (hu) 2005-01-28
DK0931081T3 (da) 2003-01-27
JP3595342B2 (ja) 2004-12-02
TW402605B (en) 2000-08-21
AU719993B2 (en) 2000-05-18
DE69715893T2 (de) 2003-01-30
CA2261923A1 (en) 1998-02-05
CA2261923C (en) 2006-01-24
ES2180041T3 (es) 2003-02-01
UA63911C2 (uk) 2004-02-16
SK283536B6 (sk) 2003-09-11
GEP20022801B (en) 2002-09-25
LT99007A (en) 1999-07-26
CN1093860C (zh) 2002-11-06
LV12260B (en) 1999-08-20
CZ2019997A3 (cs) 1999-09-15
ATE224894T1 (de) 2002-10-15
CN1228778A (zh) 1999-09-15
HUP9903104A2 (hu) 2000-03-28
NO310820B1 (no) 2001-09-03
EA199900161A1 (ru) 1999-10-28
WO1998004556A1 (en) 1998-02-05
KR100598206B1 (ko) 2006-07-07
EP0931081A1 (en) 1999-07-28
JP2000515872A (ja) 2000-11-28
FI990134A0 (fi) 1999-01-25
FI990134A (fi) 1999-03-24
HUP9903104A3 (en) 2000-04-28
EP0931081B1 (en) 2002-09-25
NO990306D0 (no) 1999-01-22
BR9710569A (pt) 1999-08-17
CZ289293B6 (cs) 2001-12-12
SI9720048A (sl) 1999-12-31
HK1020193A1 (en) 2000-03-31
FI112946B (fi) 2004-02-13
PT931081E (pt) 2003-02-28
IL128225A0 (en) 1999-11-30
ZA976612B (en) 1998-02-10
NO990306L (no) 1999-03-15
KR20000029568A (ko) 2000-05-25
LV12260A (lv) 1999-04-20
IL128225A (en) 2005-09-25
US5776935A (en) 1998-07-07
SK10399A3 (en) 2000-01-18

Similar Documents

Publication Publication Date Title
AR004158A1 (es) Compuesto de ftalizin-pirido dionas; composición farmacéutica que lo contiene; y proceso para la preparación de dicho compuesto.
CY1118191T1 (el) Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης
ECSP034562A (es) Agonista del receptor b3-adrenergico y usos de los mismos
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
ES2064310T3 (es) Procedimiento para preparar compuestos de imidazopiridina.
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
ES2112650T3 (es) Sales de un derivado de indol antimigraña.
ES2196377T3 (es) Derivados de naftiridina.
ES2185999T3 (es) Derivados de quinazolina y composiciones farmaceuticas que los contienen.
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
BRPI0313942C1 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
NO20043367L (no) Oralt farmasoytisk preparat
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
ES2179353T3 (es) Antagonistas muscarinicos.
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
ES2158813B1 (es) Sales cuaternarias de piperidina antagonistas del receptor ccr-3
PA8495101A1 (es) Derivados de 13-metileritromicina
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip

Legal Events

Date Code Title Description
FG Grant, registration